Korean J Obstet Gynecol Search


Korean Journal of Obstetrics & Gynecology 1998;41(9):2323-2328.
Published online January 1, 2001.
Second-line Chemotherapy with Taxol Containing Regimen in Recurrent or Refractory Ovarian Carcinoma after Platinum-Based Chemotherapy.
M H Kim, N H Park, Y B Kim, C M Lee, J W Kim, Y S Song, S B Kang, H P Lee
Second-line Salvage chemotherapy with Taxol Containing Regimen in Recurrent or Refractory Ovarian Carcinoma after Platinum-Based Chemotherapy. OBJECTIVES: This study is to investigate the efficacy and toxicity of Taxol containing regimen used as a salvage therapy. METHODS: Between April 1994 and October 1997, 31 patients aged 20~70 years (median 53) with recurrent or refractory ovarian carcinoma were given Taxol-containing regimen. Taxol was administered at a dose of 135 mg/m2 intravenously with cisplatin or carboplatin every 3 weeks. The patients who treated with Taxol only were received 175 mg/m2 intravenously with same interval. The median treatment cycle was 7.4 cycles (range, 3 to 12 cycles). Patient`s response were evaluated with tumor marker (CA-125) and CT or MRI before and after chemotherapy. Responses and toxicities were defined according to the Gynecologic Oncology Group criteria. RESULT: The overall clinical response rate was 35.5% (11/31), including 9 complete response (CR) and 2 partial response (PR). Better response was observed in patients who had response with prior platinum based chemotherapy (6/11, 54.5%) than who did not (5/20, 25%). The median duration of follow up was 13.4 months (range, 3 to 40 months) and the median progression free interval was 10.1 months (range, 1 to 22 months); 15.5 months (range, 11 to 22 months) in platinum sensitive group and 8.3 months (range, 1~16 months) in platinum resistant group. The most common and dose limiting toxicity was neutropenia, and grade 4 toxicity occurred in 10% of courses. CONCLUSION: Taxol containing regimen is useful combination chemotherapy in patients with previously platinum-sensitive patients with acceptable toxicity, but has limited role in chemo-refractory cases. Further prospective randomized trials are required to assess the optimal role of this drug in the management of ovarian cancer.
Key Words: Ovarian cancer, Platinum, Taxol, Second-line Chemotherapy

Article category

Browse all articles >


Browse all articles >

Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea
Tel: +82-2-3445-2382    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2021 by Korean Society of Obstetrics and Gynecology.

Developed in M2PI

Close layer
prev next